Drug Topics
APRIL 18, 2024
As the potential grows to use emerging bispecifics in earlier lines of myeloma therapy, so does the potential to induce better patient outcomes, said Kirollos Hanna, PharmD.
Pharmacy Times
APRIL 17, 2024
If approved, the test could provide more timely and accurate diagnosis, hopefully mitigating the impact of Alzheimer disease (AD) on individuals and the community.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
IDStewardship
APRIL 14, 2024
In this article a comparison of Rebyota versus Vowst is provided, to help learners differentiate these two fecal microbiota therapies. Authored by: Natalie Boyer, Pharm.D. Candidate 2025 Mentored by: Christina G. O’Connor, Pharm.D., PharmD, BCPS, BCIDP, AAHIV-M Disclaimer : This text and table is intended for use as a study tool to assist people learning pharmacotherapy of recurrent Clostridioides difficile infections (rCDI).
STAT
APRIL 18, 2024
As two former secretaries of Health and Human Services, we are all too familiar with the struggle of finding narrow openings for bipartisanship. Despite our different approaches, we believe that addressing health care costs is a truly bipartisan issue. To be serious about creating access for people to the best possible care, that care must be affordable for patients and taxpayers.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Fierce Pharma
APRIL 17, 2024
One-year data continued to support a more convenient, injectable version of Roche’s blockbuster multiple sclerosis (MS) drug Ocrevus ahead of an FDA decision, the Swiss pharma said. | One-year data continued to support a more convenient, injectable version of Roche’s blockbuster multiple sclerosis drug Ocrevus ahead of an FDA decision, the Swiss pharma said.
Fierce Healthcare
APRIL 17, 2024
Though physicians are quickly growing more comfortable with generative AI, the vast majority expect models to be transparent and trained on credible information, a new
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
APRIL 17, 2024
Ustekinumab (Stelara; Janssen Immunology) is a human monoclonal antibody that treats immune-mediated diseases such as psoriasis and psoriatic arthritis.
STAT
APRIL 18, 2024
An ongoing investigation into data integrity at Dana-Farber Cancer Institute has resulted in a string of retractions, the latest of which is a 2006 Science paper co-authored by institute president and CEO Laurie Glimcher. The retraction notice, published in Science on Thursday, noted that the authors had become aware of discrepancies in key scientific images that led them to lose confidence in key figures in the study, although the study’s lead author opposed the retraction.
Fierce Pharma
APRIL 18, 2024
During a busy period of overhaul at Sanofi, the company is restructuring its U.S. vaccine commercial group. | During a busy period of overhaul at Sanofi, the company is restructuring its U.S. vaccine commercial group. A spokesperson said the company would offer affected employees a chance to apply for new roles, plus "outplacement services.
Fierce Healthcare
APRIL 16, 2024
UnitedHealth Group released its first-quarter earnings Tuesday morning as the industry continues to reel from the massive cyberattack on its Change Healthcare unit. | UnitedHealth Group released its first-quarter earnings Tuesday morning as the industry continues to reel from the massive cyberattack on its Change Healthcare unit.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Drug Topics
APRIL 18, 2024
Kathy Campbell, PharmD, discusses why she believes wellness and proactive health are the future of pharmacy and the unique value they offer compared to traditional models.
Pharmacy Times
APRIL 18, 2024
Through recognizing the importance of research in the scope of pharmacy practice by national pharmacy organizations, research can become a prominent role and responsibility of pharmacy.
STAT
APRIL 18, 2024
For a company moving as quickly as possible to build artificial intelligence into everything — including health care — Microsoft spends a lot of time talking about how to regulate it. The tech giant has helped organize four separate coalitions to devise guidelines and technical standards for AI in health care. It supplies these groups — composed of health systems, government regulators, and other health businesses — with top executives to serve on steering committees,
Fierce Pharma
APRIL 18, 2024
Novo Nordisk is receiving pushback from a trio of lawmakers over its decision to discontinue its long-acting insulin product Levemir, which was due for a steep discount at the start of the new year | Novo Nordisk is receiving pushback from a trio of lawmakers on its decision to discontinue its long-acting insulin product Levemir, which was due for a steep discount at the start of the new year.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Healthcare
APRIL 16, 2024
The House Energy & Commerce subcommittee on innovation will hold a hearing Wednesday to discuss data privacy and the protection of kids online. | The House Energy & Commerce Committee holds a legislative hearing to discuss a slate of privacy and online safety bills Wednesday, one of which would give consumers more control over health data collected by apps and big tech.
Drug Topics
APRIL 18, 2024
Nine pharmacists from 2 corporate locations in Wakefield and Westerly are seeking to join the Pharmacy Guild in an attempt to improve working conditions.
Pharmacy Times
APRIL 18, 2024
Eli Lilly and Company will submit results of the study to support tirzepatide (Zepbound) for treatment of obstructive sleep apnea later this year.
STAT
APRIL 17, 2024
Eli Lilly reported positive results for its obesity drug Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market. The results also pave the way for Zepbound to potentially become the first approved treatment for obstructive sleep apnea, or OSA, a common disorder characterized by breathing interruptions during sleep.
Fierce Pharma
APRIL 17, 2024
In addition to their acclaimed efficacy against diabetes and obesity, GLP-1 drugs are gaining traction for their potential to treat a variety of other common disorders. | In addition to their acclaimed efficacy against diabetes and obesity, GLP-1 drugs are gaining traction for their potential to treat a variety of other common disorders. Now, two trials have shown that Eli Lilly’s weight loss product Zepbound (tirzepatide) can help patients overcome obstructive sleep apnea (OSA).
pharmaphorum
APRIL 16, 2024
A smart sensor developed by Adherium has been cleared by the FDA for use with AstraZeneca's asthma inhaler Airsupra and Breztri for COPD.
Drug Topics
APRIL 15, 2024
In the United States, 12 million adults suffer from co-occurring chronic pain and anxiety or depression. Erasing stigmas, educating patients, and tailoring interventions can help to improve outcomes.
Pharmacy Times
APRIL 17, 2024
The product is currently being investigated alongside TLX101 in the IPAX-Linz and IPAX-2 clinical trials, and have previously shown efficacy in the IPAX-1 trial.
STAT
APRIL 18, 2024
In the chaotic first few months of the Covid-19 pandemic, stores faced shortages of all kinds — toilet paper, canned food, and especially, cleaning supplies. With everyone scrubbing their groceries, mail, even library books, good luck finding antibacterial wipes or disinfectant sprays back then. That’s because public health advice in early 2020 focused on sanitizing surfaces, not protecting against a virus that could be spread through the air.
Fierce Healthcare
APRIL 14, 2024
Medical records software giant Epic and venture-backed health tech company Particle Health are mired in an ongoing dispute over healthcare data exchange practices. | Health IT experts say the rift between the two companies exposes larger problems with health data exchange including a lack of transparency on who is accessing data and how it's being used along with the need for better gatekeeping.
Pharmaceutical Technology
APRIL 18, 2024
Outrun Therapeutics announced its launch with $10m seed funding to advance a protein stabilisation pipeline focused on E3 ligase inhibitors.
Drug Topics
APRIL 17, 2024
Researchers were unable to find a significant benefit for patients for the majority of cancer medications given accelerated FDA approval.
Pharmacy Times
APRIL 17, 2024
IMPACT CKD, a modeling analysis created by AstraZeneca, includes data about chronic kidney disease across 8 countries, including the United States.
STAT
APRIL 17, 2024
A new analysis of health inequities in the United States shows that every state has deep racial and ethnic disparities in the performance of their health care systems. The report released Thursday by the Commonwealth Fund analyzed 25 indicators that track health outcomes, health care access, and quality of care provided for five racial and ethnic groups.
Fierce Pharma
APRIL 15, 2024
A Novartis drug with "pipeline in a pill" potential, according to one analyst group, has delivered on that promise once again. | In a phase 3 trial, treatment with Fabhalta led to a statistically significant 38.3% reduction of proteinuria (protein in the urine) in patients with IgA nephropathy, Novartis said on Monday.
pharmaphorum
APRIL 18, 2024
UK researchers describe an algorithm that is more accurate than current tools at predicting an individual’s risk of developing cardiovascular disease in the next 10 years.
Drug Topics
APRIL 12, 2024
Although over 38 million people in the US have diabetes, continuous glucose monitor (CGM) uptake is low. Community pharmacists are uniquely positioned to promote uptake due to their frequent interactions with patients and expertise in chronic condition counseling.
Pharmacy Times
APRIL 16, 2024
Sa’ed Al-Olimat, PharmD, co-founder of the Psychedelic Pharmacists Association, discussed the future of psychedelic medicines and the unique ethical challenges they present.
STAT
APRIL 17, 2024
When my son Conall took his life at age 17, it was devastating to me and our entire family. Conall was a caring, empathetic, and bright young man, but he had also struggled for many years with anxiety and depression. Like many kids his age, much of his life revolved around social media. While I understand that suicide is complex, with many different factors contributing to someone’s risk for it, I know that social media intensified and fueled Conall’s insecurities and ultimately ha
Fierce Pharma
APRIL 18, 2024
Amgen CEO Robert Bradway scored a 5.8% increase in overall compensation last year mostly thanks to the company’s acquisition of Horizon Therapeutics. | Amgen CEO Robert Bradway scored a 5.8% increase in overall compensation last year mostly thanks to the company's acquisition of Horizon Therapeutics.
Expert insights. Personalized for you.
217 
Let's personalize your content